RespireRx Pharmaceuticals Inc (CE) (RSPI) Share Price

Maybe. 8 bucks at a time while the company wastes significant time waiting for ??? To communicate and present to stakeholders and potential resources, collaborators, talent and partners?

Someone who understands the extraordinary potential, has access to EM, and wants to keep the price super low in order to accumulate more at a ridiculous price befoe RSPI explodes?

Yep. Many feel exactly the same and wondering WTF?

The company touted their exceptional SEC reporting history for years. Knew they were in line for DOD funding phase 2. They can’t hide their excitement for preclinical darling KRM-II-81 and NIH grant possibilities. And the OSA program has competitors advancing on less and RSPi’s dronabinol licensor UIC in an upcoming phase 1/2 with VA sponsorship!!

So what does it mean that they went radio silent??? IMO big time money is at the door…

Highly desirable assets is what they have presented to investors in the past! Their 3 asset platforms are only better positioned and more valuable today! Those whom invested are glad to own a piece of these assets despite it all…

Hence why this expert market is really a joke.

Who benefits from a last minute reset of the price as such on an $8 trade??

Inexcusable to end the year still on EM after half of 2024 spent there and with zero communication to shareholders. 

Hey Jeff, you're a public fking company, start acting like it. You have a fiduciary duty to shareholders. 

Said it before and I'll say it again, even the corrupt scamming clowns over at ENZC managed to keep a small bio pink current. 

Curious last trade of the year. Is this an effort to keep the price ridiculously low?

May we all prosper in the New Year which I suspect will be augmented by RSPI.

Hopefully we wake up tomorrow to the eoy share holder letter that has been swirling around

Thank you, LTListener. Happy New Year to you as well!

Happy New Year to all.

Wishing all the best of health and happiness in the new year. And just maybe, the powers at be here will turn the page and bring these premier assets to new heights in clinical trials in 2025.

The CEO of OTCMarkets provided an update to that March of 2021 article in September of 2023:
https://blog.otcmarkets.com/2023/09/14/the-expert-market-its-larger-role-post-rule-15c2-11/

https://blog.otcmarkets.com/2021/03/25/understanding-the-expert-market/

It's simple really:
OTC Markets Group operates the Expert Market.
Quotations in Expert Market securities are restricted from public viewing.
Only broker-dealers and professional or sophisticated investors are permitted to view quotations in Expert Market securities.
(above per OTCMarkets)

Bid 0.00
Ask 0.00
https://ih.advfn.com/stock-market/USOTC/respirerx-pharmaceuticals-ce-RSPI/stock-price
https://www.otcmarkets.com/stock/RSPI/quote


You can buy or sell RSPI shares if you can find a broker willing to take the trade and are willing to do so without a quote.
I believe the B/A numbers you are seeing here are actually based on the latest trading activity and not actual offers to buy and sell.

jmo

Yeah I don't understand where the b/a is coming from with no centralized platform. I wonder if what is reported here is just individual brokers b/a and it could be completely different at another brokerage.

Regardless, the EM trading is ridiculous situation for pharma assets heading into clinical trials.

10K 0.0024
1,100,000 0.0011

What b/a?

There isn't any bid and ask lol
That's the effect of being on the Expert Market.

It is all bread crumbs in terms of volume on the EM.

They need to ink some small level of funding to get the filings current and convey a strategy with the assets going forward. Use a little bit of funds and a little effort into communication and presentation of the company and the pps will be back to where they left off. Get current and then provide updates of the assets: DOD phase 2, NIH grant phase 1, OSA clinicals/FDA status, etc. By the time they exit the EM and get the clinicals in motion on these assets the stock can be .05 +/-... Let clinical success and BP partnerships bring in the big whales and send it to a quarter....

Exactly, we need to get through $0.0025.

0,0025

Well they stated in 8-k to rectify situation they were seeking funding. The most logical explanation is they have been negotiating a significant funding deal and isolating the noise on this EM and pushing deals into 2025 had significant advantages.

There is a school of thought that trading on this expert market could allow institutional and accredited type investors to absorb the float as news is continually released and the share price rises into the pennies and nickels and retail reduces their collective positions. Consolidating the float for future sustained levels of dimes and quarters as they garner success in clinical trials..

Who knows but the last 6 months has been more than irrational, I am ready to see that pendulum swing the other way!

Looking good for next year. GLTA HB

Nevertheless if the trends continues RSPI might still do well even inside the expert market. Where it’s somewhat shielded from fads, and mass hysteria.

This seems to have happened a few times already, starting with their Cortex days. This is a model case for the constitutive dead angles of finance and capitalism as it exists now. It’s an engine of creation, but things still fall in the cracks.

maybe they are waiting for a new SEC head lol

there is definitely a good reason that they needed a pause from the market, i believe those who held will be rewarded smartly!!

LT - I wonder if the strategy is to reemerge with so much to present in neuropharmacology, that they are aiming to garner enough attention in the investment world that an "irrational" price momentum will take hold and far exceed the valuation of the company. We have seen this frequently with many companies over the past 30 years.

Market report from Insight Ace Analytics mentions RespireRx:

Cannabinoid Derived Pharmaceutical Market Size, Share & Trends Analysis Report By Product (Natural (Plant-derived), Synthetic Cannabinoid), By Molecule Type (Cannabinoid Receptor Type 1 (CB1), Cannabinoid Receptor Type 2 (CB2), Others), By Disease Indication, By Region, And Segment Forecasts, 2023-2030.

Report ID : 1042 | Published : 2024-10-04 | Pages: 180 |

Competitive Landscape

Some Of The Key Players In The Cannabinoid Derived Pharmaceutical Market:

Cara Therapeutics, Inc.
Arena Pharmaceuticals (Pfizer)
Cannabics Pharmaceuticals Inc.
GW Pharmaceuticals (Jazz Pharmaceuticals)
InMed Pharmaceuticals
INSYS Therapeutics, Inc.
LaraPharm
MGC Pharmaceuticals, Ltd.
One World Cannabis
Orpheus Medica
Receptor Life Sciences
RespireRx Pharmaceuticals
Tetra Bio-Pharma
Cardiol Therapeutics
United cannabis Corporation
Zynerba Pharmaceuticals


https://www.insightaceanalytic.com/report/global-cannabinoid-derived-pharmaceutical-market-assessment/1042

ABNewswire

Key Mild Cognitive Impairment Companies: FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics, Inc., Avraham Pharma, AstraZeneca, Sage Therapeutics, Pfizer, Materia Medica Holding, Eli Lilly and Company, GE Healthcare, Parexel, and others

https://www.abnewswire.com/pressreleases/mild-cognitive-impairment-market-to-observe-impressive-growth-during-the-forecast-period-20232032-evaluates-delveinsight-fujifilm-toyama-chemical-co-aptinyx-agenebio-eisai-inc-respirerx_690250.html

Defense world mentions RespireRx.

https://www.defenseworld.net/2024/11/23/respirerx-pharmaceuticals-otcmktsrspi-versus-syros-pharmaceuticals-nasdaqsyrs-head-to-head-survey.html

I just want to see us past 0025 lol everytime we hit it we bounce right back down to high trips lol

What's bid and ask

Check again lol

Volume: 3

Fun math...

Today's market cap is roughly 2 million at .002 per share. Truly peanuts for pharma. Especially one with 3 different assets/platforms at various clinical trial stage!!

Many mid major pharmas with similar level assets at various clinical stages would minimally trade in the 20-40 million range (2-4 pennies) AND with any BP/funding partnerships or equity stakes coupled with some clinical success can yield 200-400 million valuations. Some OTC pharmas have run up to 1 billion valuations on much less progress in the past.

The company claims to independently value the OSA program at multiples of 20 million! IMO, the gabakine preclinical compound is probably most valuable asset and of course the DOD funded phase 2 holds value as well.

smh at the potential and what flexibility and expansion opportunities would open up if these assets could sustain reasonable valuations not even talking higher end speculative valuations. Let's hope the new year opens the flood gates here for funding and communication/presentation to maximize potential of these assets as they enter clinical trials. GLTA.

Yeah I too support their scientific approach with these platforms and the reputation and achievements of those connected to those efforts is outstanding.

The reference to attracting talent and resources is on the business side. A solid leadership team would have communicated and clearly presented these assets to the investment community with continual updates. Inking a funding deal would have been very high on priority as well as maintaining fudiciary duty and completing filings. All in the effort of positioning the company to capitalize on success at each stage: preclinical thru phase 3.

LT, "hinders all flexibility to attract talent." They already have attracted a massive amount of talent by making available virtually all their ampakines for preclinical trials to university researchers all over the world. A few of the early papers out of UCI have been cited over 200 times. Incredible! I have over 100 papers, most per-reviewed. The most my early ones have been cited is 40 or so, which is a wonderful achievement...but 200+ ???

Maybe, but I think many investors are struggling understanding the strategy for the past 7 months. They have not yet inked a major funding deal to support these 3 platforms heading into clinicals. They have not presented investors or communicated to stakeholders anything at all. With the company assets continually way undervalued, it hinders all flexibility to attract talent and collaborative resources that could expand utlization of these platforms.

I think the scientific team/approach has been solid and logical in setting up these assets on best possible paths heading into clinicals. But they need business leadership to drive valuation and establish resources to advance assets through various stages of development and those potentially massive leaps in value.

Looking forward in 2025 to hear about...

1. Status of DOD funded phase 2 SCI clinical trial. What are the milestones and how/when will this lead into ADHD trials for the ampakine platform?

2. KRM-ll-81 status with NIH grant funding and the consultants efforts in setting up trials for epilepsy. What are those milestones? Also, some color as to how successful has KRM-ll-81 truly been in those robust NIH preclinical evaluations? They continue to portray excitement with this compound. When and what are the plans to get this superior preclinical compound into trials for pain and/or anxiety?

3. OSA program update. Silent for over a year now. What is holding up progress? How is their licensor UIC conducting VA sponsored dronabinol trials early next year related? Has the strategy changed with the FDA and progress of competitors?

4. Improving communication and presentation. Clearly there is massive potential with their platforms and it is amazing to have 3 different platforms in various clinical trial stages. The ingredients for becoming a special pharma company is there. What is yet needed to get funding and additional talent resources on board for this company to take off? What is holding it back?

Considering how undervalued and in the shadows this company has been, I think 2025 could be something special. GLTA.

Considering Lippa's business credentials, there is no doubt in my mind that what appears to be madness, there is carefully calculated method.

That’s just a cynical commentary. The irony is unless you are an “expert” you haven’t been able to acquire a position in about 6 months..

Who knows, but market interest won’t pick up until about mid January. They really need to convey a strategy to build resources, build out shareholder base and capitalize on significant position and progress of 3 pipeline platforms all into clinical trials. The lack of communication and presentation and undervaluing your assets can only hinder execution on opportunities. Hoping the new year brings a smarter approach.

I agree, logistically not near ideal compared with various dronabinol efforts which is simpler with minimal side effects..

Maybe Lilly would be interested in RSPI pipeline to fill in the cracks.. several from science team and the VP hire a year ago has a history with them..

Where did he say that at?

Pharmacological modulation of hypoxia-induced respiratory neuroplasticity

Sara Turner , Kristi Streeter , John Greer, Gordon S Mitchell, David D Fuller

PMCID: PMC6155458 NIHMSID: NIHMS987117 PMID: 29197629
Respir Physiol Neurobiol. 2017 Nov 29;256:4–14. doi: 10.1016/j.resp.2017.11.008
Abstract
Hypoxia elicits complex cell signaling mechanisms in the respiratory control system that can produce long-lasting changes in respiratory motor output. In this article, we review experimental approaches used to elucidate signaling pathways associated with hypoxia, and summarize current hypotheses regarding the intracellular signaling pathways evoked by intermittent exposure to hypoxia. We review data showing that pharmacological treatments can enhance neuroplastic responses to hypoxia. Original data are included to show that pharmacological modulation of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) function can reveal a respiratory neuroplastic response to a single, brief hypoxic exposure in anesthetized mice. Coupling pharmacologic treatments with therapeutic hypoxia paradigms may have rehabilitative value following neurologic injury or during neuromuscular disease. Depending on prevailing conditions, pharmacologic treatments can enable hypoxia-induced expression of neuroplasticity and increased respiratory motor output, or potentially could synergistically interact with hypoxia to more robustly increase motor output.

“Pharmacologic approaches may also reduce the number of hypoxic episodes necessary for activating intracellular pathways necessary for sustained increases in respiratory and somatic motor output (e.g., ampakines, see section 4.1). “

Thank you to all those that bought this year - Jeff

I'm betting it's after

Do we see a shareholders letter before or after the 1st of year

Increase in Disease since 1990

This just in: New market report mentioning RespireRx:

Global Circadian Rhythm Sleep Disorder Industry Trends Analysis Report 2024, Forecast to 2032 (Broken Down by Type, End User, Regional Analysis, and Competitive Landscape)
Publisher: Maia Research
Published Date: December, 2024
SKU: MAIR19435983

Key players in the global Circadian Rhythm Sleep Disorder market are covered in Chapter 4 and Chapter 8:

Jazz Pharmaceuticals
Respirerx Pharmaceuticals
Glaxo Smith Kline
Boehringer Ingelheim
Fabre-Kramer Pharmaceuticals
Neurocrine Biosciences
Arena Pharmaceuticals
Merck and Co

https://www.marketresearch.com/Maia-Research-v4212/Global-Circadian-Rhythm-Sleep-Disorder-39121181/